Foghorn Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Foghorn Therapeutics Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue22.6034.1619.231.320.43
Cost of Revenue0.00109.69105.6280.3357.72
Gross Profit22.60-75.5319.23-79.01-57.29
Operating Expenses
Research & Development94.53109.69105.6280.330.00
Selling, General & Administrative28.3632.3730.7521.7311.25
Operating Expenses125.29142.06136.3721.7311.25
Operating Income-102.68-107.91-117.14-100.73-68.53
Other Income/Expense
Interest Income11.9010.885.680.060.10
Interest Expense0.000.000.00-1.91-0.98
Other Income/Expense16.062.832.582.490.83
Income
Income Before Tax-86.62-94.20-108.88-101.32-68.80
Income Tax Expense0.004.230.000.000.00
Net Income-86.62-98.43-108.88-101.32-68.80
Net Income - Continuous Operations-86.62-98.43-108.88-101.320.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-97.17-104.46-113.82-97.51-67.20
EBIT-86.60-107.91-117.14-100.73-68.53
Depreciation & Amortization3.123.453.303.231.33
Earnings Per Share
Basic EPS-2.00-2.00-3.00-3.00-6.00
Diluted EPS-2.00-2.00-3.00-3.00-6.00
Basic Shares Outstanding54.9041.9741.5937.1711.05
Diluted Shares Outstanding54.9041.9741.5937.1711.05